Application Detail

Description of Medical Service

¹⁷⁷Lutetium(nca)-DOTA-octreotate is a radiopharmaceutical administered by infusion to patients with progressive or symptomatic Neuroendocrine Tumours (NET) if molecular imaging techniques demonstrate much higher levels of somatostatin receptors on the majority tumours sites compared to normal tissues. The initial treatment cycle most commonly comprises 4-5 infusions, given 6-8 weeks apart, and responding patients may be re-treated multiple times if symptoms recur or further tumour progression occurs.

Description of Medical Condition

Neuroendocrine tumours arise in a range of tissues from cells that function to regulate bodily function by secreting bioactive compounds, particularly peptide hormones. These tumours can be slowly or aggressively growing with excessive hormone secretion often adversely affecting the patient’s quality of life in lower-grade tumours, while high-grade tumours cause compromise of organ function and tissue integrity leading to premature death.

Reason for Application

New MBS item

Medical Service Type

Therapeutic technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1675 KB)
Application Form (Word 1001 KB)

Consultation Survey

Consultation Survey (PDF 653 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
PASC consultation closed

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 14 June 2024 for it to be considered by MSAC at its August 2024 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

PICO Confirmation (PDF 2655 KB)
PICO Confirmation (Word 2954 KB)

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

13-14 April 2023
10-11 August 2023

ESC

13-14 June 2024

MSAC

1-2 August 2024